Advertisement

Table of Contents

October 26, 2017; 130 (17)

INSIDE BLOOD COMMENTARIES

PERSPECTIVES

CLINICAL TRIALS AND OBSERVATIONS

  • Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
    Claire N. Harrison, Adam J. Mead, Anesh Panchal, Sonia Fox, Christina Yap, Emmanouela Gbandi, Aimee Houlton, Samah Alimam, Joanne Ewing, Marion Wood, Frederick Chen, Jason Coppell, Nicki Panoskaltsis, Steven Knapper, Sahra Ali, Angela Hamblin, Robyn Scherber, Amylou C. Dueck, Nicholas C. P. Cross, Ruben Mesa and Mary Frances McMullin

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

RED CELLS, IRON, AND ERYTHROPOIESIS

TRANSPLANTATION

LETTERS TO BLOOD

  • WIP deficiency severely affects human lymphocyte architecture during migration and synapse assembly
    Laurène Pfajfer, Markus G. Seidel, Raïssa Houmadi, Javier Rey-Barroso, Tatjana Hirschmugl, Elisabeth Salzer, Inés María Antón, Christian Urban, Wolfgang Schwinger, Kaan Boztug and Loïc Dupré
  • Origins of myelodysplastic syndromes after aplastic anemia
    Eiju Negoro, Yasunobu Nagata, Michael J. Clemente, Naoko Hosono, Wenyi Shen, Aziz Nazha, Tetsuichi Yoshizato, Cassandra Hirsch, Bartlomiej Przychodzen, Reda Z. Mahfouz, Teodora Kuzmanovic, Mikkael A. Sekeres, Hideki Makishima, Seishi Ogawa and Jaroslaw P. Maciejewski

BLOOD WORK